Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

A hospitalized patient triggers a major setback for Intellia's $1.9B flagship drug, shaking investor faith overnight ...

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...

Intellia Therapeutics said it is pausing two late-stage CRISPR gene-editing trials after a patient in one study was hospitalized with liver damage.

CRISPR Therapeutics (CRSP) recently showcased new preclinical results for its CTX460 therapy, revealing strong gene and mRNA correction in animal models for Alpha-1 Antitrypsin Deficiency. The ...

Despite setbacks and funding cuts — and a quieting of the hype blaring its arrival — multiple CRISPR-based trials are ...

How can altering DNA help defeat one of the world’s deadliest diseases? This video explores how scientists are using CRISPR ...

Traditional breeding and genetic modification methods have struggled to keep pace with the rapid evolution of plant viruses.

Intellia Therapeutics will find it challenging to survive now that its CRISPR gene-editing treatment has been tied to severe, ...

On June 28, 2012, the most significant scientific breakthrough of the first quarter of the 21st century was announced to the ...

CRISPR Gene Editing Market To Hit $12.78B By 2033, Kits & Reagents 60.5% Share, Cas9 Drives Innovation. EINPresswire/ -- CRISPR Gene Editing: A Technological Overview CRISPR gene editing has ...

CRISPR is a gene-editing tool that acts like “molecular scissors,” but using it on cancer is complex. The technology’s biggest impact so far is in research labs, helping scientists understand how ...